跳转至内容
Merck
CN
  • Secondary prevention of coronary artery disease in Poland. Results from the POLASPIRE survey.

Secondary prevention of coronary artery disease in Poland. Results from the POLASPIRE survey.

Cardiology journal (2020-05-22)
Piotr Jankowski, Dariusz A Kosior, Paweł Sowa, Karolina Szóstak-Janiak, Paweł Kozieł, Agnieszka Krzykwa, Emilia Sawicka, Maciej Haberka, Małgorzata Setny, Karol Kamiński, Zbigniew Gąsior, Aldona Kubica, Dirk De Bacquer, Guy De Backer, Kornelia Kotseva, David Wood, Andrzej Pająk, Danuta Czarnecka
摘要

The highest priority in preventive cardiology is given to patients with established coronary artery disease (CAD). The aim of the study was to assess the current implementation of the guidelines for secondary prevention in everyday clinical practice by evaluating control of the main risk factors and the cardioprotective medication prescription rates in patients following hospitalization for CAD. Fourteen departments of cardiology participated in the study. Patients (aged ≤ 80 years) hospitalized due an acute coronary syndrome or for a myocardial revascularization procedure were recruited and interviewed 6-18 months after the hospitalization. Overall, 947 patients were examined 6-18 months after hospitalization. The proportion of patients with high blood pressure (≥ 140/90 mmHg) was 42%, with high low-density lipoprotein cholesterol (LDL-C ≥ 1.8 mmol/L) 62%, and with high fasting glucose (≥ 7.0 mmol/L) 22%, 17% of participants were smokers and 42% were obese. The proportion of patients taking an antiplatelet agent 6-18 months after hospitalization was 93%, beta-blocker 89%, angiotensin converting enzyme inhibitor or sartan 86%, and a lipid-lowering drug 90%. Only 2.3% patients had controlled all the five main risk factors well (non-smoking, blood pressure < 140/90 mmHg, LDL-C < 1.8 mmol/L and glucose < 7.0 mmol/L, body mass index < 25 kg/m2), while 17.9% had 1 out of 5, 40.9% had 2 out of 5, and 29% had 3 out of 5 risk factors uncontrolled. The documented multicenter survey provides evidence that there is considerable potential for further reductions of cardiovascular risk in CAD patients in Poland. A revision of the state funded cardiac prevention programs seems rational.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
Suplatast tosylate, ≥98% (HPLC)